Navigation Links
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
Date:8/25/2009

NEW YORK, Aug. 25 /PRNewswire/ -- Beth R. Jacobson (formerly Beth R. Wolmer) filed suit yesterday against Celgene Corporation (Nasdaq: CELG), under the claims of "misappropriation of an idea" and "unjust enrichment" regarding the Company's sale of thalidomide (THALOMID(R) and REVLIMID(R)) for the treatment of multiple myeloma. The suit alleges that Ms. Jacobson developed the original and novel idea for treating multiple myeloma with thalidomide and is therefore entitled to compensation consistent with established legal precedent. Ms. Jacobson is represented in this suit by Goodwin Procter LLP.

The suit, which was filed in U.S. District Court in Newark, New Jersey, seeks a minimum of $300 million as past damages and 25 percent of the future profits resulting from the sale of Celgene's thalidomide products (THALOMID(R) and REVLIMID(R)) for the treatment of multiple myeloma.


'/>"/>
SOURCE Beth R. Jacobson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
2. ASCP Joins ACLU Lawsuit Opposing Gene Patents
3. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
4. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
5. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
8. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
9. Two New Jersey Hormone Therapy Lawsuits Dismissed
10. Protein Sciences Responds to Emergent BioSolutions Lawsuit
11. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... for the detection and quantification of partially hydrolyzed gluten in foods, has been ... Board adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), ... (MS), today announced that the independent Data Safety Monitoring ... MAESTRO-03 trial of dirucotide in patients with secondary progressive ... the trial continue as per the protocol. , This ...
... Calif., April 14 Zenobia Therapeutics, Inc., the ... the central nervous system, announced successful completion of ... Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec ... the agreement, Syntonix gains access to Zenobia,s technology ...
... Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) provides ... 2009 third quarter and nine-month period ended February 28, ... fiscal year 2009 now ending on February, 28. , ... February 28, 2009 in the range of $3,400,000 to ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... international team of researchers led by investigators in the U.S. and ... a common cell cycle that fuels growth in plants, animals and ... of the Earth,s biomass. This discovery, led by a geneticist at ... Nature , leads to a new understanding of how cells grow ...
... at a school beside an informal electronic waste salvage ... lead, cadmium and other health-threatening pollutants over 50 times ... church headquarters and a soccer field are likewise polluted ... metal site, where electronic trash is scavenged for valuable ...
... 29, 2011) A major public symposium at Boston College ... day-long examination of the contributions of the physical and social ... ,Science in the Liberal Arts University Why It ... by BC,s Institute for the Liberal Arts, takes place today ...
Cached Biology News:Research team clarifies mechanics of first new cell cycle to be described in more than 20 years 2Research team clarifies mechanics of first new cell cycle to be described in more than 20 years 3High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 2High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 3High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 4High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 5Science in the liberal arts university 2
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
... 8G8/5 GenBank Accession Number : NM_002542 ... fusion protein corresponding to residues 166-223 of ... AP-2γ Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M ... of glycerol to 30% Quality Assurance: routinely ...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... a lesser extent in breast, lung and ... shows no cross-reaction with MUC1 and MUC2. ... human MUC3 Immunogen: MUC3 tandem ...
Biology Products: